Member Info for PM2022

Phimx,

It's far more complicated than you think. They are building an AI company with other drugs and also helping with 301. No point going into detail but the best thing in your case is to look at other companies.

You need to watch all the presentations on the website and not ask questions here. DYOR

Best Wishes,

End of FY23 and nothing about costs just for staff with the stated amount. Now you pretend you can’t understand what was written. Clearly says 200k to run the laboratory which would include the rent and other costs.

Looks positive to be fair. Extra revenue will come through to cover costs with faster evaluations. 10p a bargain for those that can afford it.

Most people kind of expect Barcelona to go into SPV but given it's been a while since the deadline then you would expect that it has been successful. That would give us two world class novel preclinical projects. Surely we would be worth no less than 30p with that alone and that without 201 and 301 which Suzy is very confident will progress. Crazy value on offer.

From the VAL website.

Once the Evaluation is complete, a negotiation period is entered to set up the subsidiary and executed the license, after which the project is promoted to our in-house pipeline. Once we receive updates regarding manufacturing, product developments and formulation developments within the evaluation pipeline, we update our shareholders and this webpage accordingly.

TP note suggested lab staff increases only when revenue starts coming through. Therefore not really relevant.

Never thought you would get anything near 100k each working in a lab as a standard lab scientist especially in Nottingham. Just making up figures to suit your agenda.

See you in July, I don’t want to **** of holders. DYOR,GL, let’s see how this plays out. Pork's.

Yes but she is not the lead scientist here. Completely different roles. CLX is managed by Zia Ahmad now if you can pull negatives about her then we will be happy to listen.

Irrelevant. Completely different staff and management with almost full patent life compounds. Do some research on Zia Ahmad pre-clinical project lead.

Great post from Adam today. The only one that some of us can learn from here.

Recent oncology dealmaking trends provide insights on strategies for dealmaking in the current market.

Early dealmaking appears to be the norm in oncology nowadays, as 73% of non-acquisition deals from 2015 to 2022 involved preclinical ventures.

Mean preclinical oncology acquisition deal – 359M; mean licensing deal – 540M; mean partnering deal – 985M (all USD). We have a MCap of 10M USD.

The mean deal values of partnering or licensing deals occurring at phase 1 were even lower than those occurring at the preclinical stage, though the upfront payments were slightly higher. Contrary to the common belief, the data suggest that oncology ventures don’t become a lot more valuable once they enter the clinic. No evidence was found for the necessity to clinically de-risk a platform technology. On the contrary, about half of the platform companies were still preclinical at the time of the deal.

Given the fierce competition in oncology nowadays, big pharma can no longer afford to sit on their hands waiting for the next-generation technology to be validated in the clinic.

Atlas have recognized this and developed a different business model for 24% of their portfolio companies, which is called the special purpose vehicle (SPV) or LLC holding company model. In these types of company structures, there is a holding company that has the platform IP and separate subsidiaries (each an SPV) for individual programs that contain target-specific IP. This model is ideal for platform companies and has been successfully used by companies such as Nimbus, F-star and Teneobio.

SPVs can leverage the full economic potential of a platform, but also create tremendous flexibility. A company could progress an SPV to a bigger value inflection point when it has capital available to do so, or alternatively, seek a risk- and resource-sharing partnership to reap more of the commercial benefits. This makes sense when capital from the private and public markets is readily available. Conversely, in cases of economic downturns, like the bear market we are facing right now, a company can focus resources on its mission-critical SPVs and seek licensing or acquisition deals for non-core SPVs.

So, it turns out the BOD are two years ahead of the curve on this. Credit where it is due.

https://www.nature.com/articles/d43747-023-00002-6

Wait for the momentum to come when RNS comes at this market cap. We are due Barcelona and personally I think 201 will come with it soon before or soon after.

Decent chance after hours or Monday RNS. At 9 million market cap with a top shelf pre-clinical could really give us great momentum.

Make sure you sign up for the RNS alert. Could this be because the VAL 201 deal is about to be announced as well? Must be a reason.....Watch this space.

https://twitter.com/valirxplc/status/1639240402485248000?s=52&t=fCEY9_9hZF2UlWCBUkqqHQ

Metom , It was for the lab set up, equipment, hiring staff and having a decent balance to attract lab staff as they want to join a stable company with cash. Nothing was due at that time so they did it at the price.

Moving forward we got Barcelona, 201, 301 and Hokkaido due. Even if one was successful we should move a fair amount. Happy to wait and see.

Always best to look at best case and worst case situations.
Worst case:
201 deal fails
301 bad news fails
Barcelona evaluation fails
Hakkaido evaluation fails
zero lab contracts

We then still have CLX and a lab. We should still be in the 20p/20 Million market cap range.

Best case.

Barcelona passes
201 deal completes
301 positive findings/progress
Hakkaido evaluation passes
Lab contracts.
.
We also have CLX and a lab. Anywhere between 50-100p short term for best case imo. Somewhere in the middle still multiples of the current SP for some success and failure.

The rIsk to reward suggests a strong buy at the current SP. Factor in Suzy stating she is expecting progress on the evaluation projects and legacy assets then you should be onto a big winner. DYOR.

Don't see the point of negativity if you are holding as you lot are just shooting at yourselves. Give it until June.

Lots of news due. Personally I would want the share price to be at least 20 p range by June and to be fair we should be much higher but some would then give her the benefit of doubt.

TRX and Suzy know 201 is very important to get done before June and I think it will.

Therefore it’s possible with 2/3 RNS in quick succession. It needs anticipation or big news.

Wrong. Intraday price. It went to 65 p all holders know that and you were not one.

Outstanding news due. Market cap only 9 million and well funded.

Barcelona due now. Estimated value at least 10 p to our market cap. Decent chance of success.

201 outcome absolutely huge upside to the current market cap and again surely must be at an advanced stage by now. Previously went to 65 p and 74 p based on 201 results and deal which was not funded at the time.

Hakkaido due in June another potential minimum 10 p to the current SP.

CLX001 updates the true value of this will start getting priced in with another update. If we get data might be worth at least 20p on its own.

Lab contracts with decent revenue to come.

301 findings outcome.

I just don't see everything failing so a great buy and we have cash until the end of this year. We should still be worth more than double at the moment even without news imo due to false down.

False down from last year due to 201 delay then placing at 10 p. Assets have increased in value since with CLX being added and Barcelona and Hakkaido now due or due shortly. Throw is 201 after all this time it can only take so much longer. Potential of positive outcomes have increased.

All psychology. What matters is that we have plenty of cash for this year and lots of news priced at zero. Only a few know that these are the times to buy and hold.

VAL301 gets a mention on Twitter. Never a failure after all this time. It will come and so will 201 and so will Barcelona.......

This is why I will be holding and expecting a move around the 50p mark as I worked it out in my mind. Obviously difficult to predict but this is how I see it.

1) Barcelona successful- Moves to 20p range should be no less than 30p imo with two novel world class pre clinical projects plus lab without 201.

2) Followed shortly by either positive findings for 301 moving into full preclinical or/and 201 deal completed. That should take us comfortably to the 30p-60p range before June.

3) News regarding the lab/contract news.

4) With price around settling around 50p Val does a placing later in the year maybe around 35p mark for about 3-5 million with 0.5-1 million going towards asset two which will help bring more revenue and bigger contracts. They have flexibility in regards to the timing of this as Val is well funded at the moment so after lots of news.

5) Followed by CLX data update or Hakkaido depending on timing taking us back to 60/70p plus.

6) Institutional investors make it more likely we reach at least 60-70p in the next 6 months and I think we will get one or two following some outcomes.

Based on the clip posted below it does look fairly certain we will get success for either 201 or 301 and another SPV. Possibly both for legacy and 1/2 for evaluation. Suzy has been very positive about 301 in all her presentations and they remain confident of 201 so I think both will get through with at least 1 before June.

We can only really be at this price if everything fails but still we should be higher with CLX and a lab. Highly improbable all fails and most of this is likely to happen before the June votes so a great buy.

I will keep holding as I see this plan working and it makes sense to me.